These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20421623)

  • 1. Stemness characteristics of fibrolamellar hepatocellular carcinoma: immunohistochemical analysis with comparisons to conventional hepatocellular carcinoma.
    Zenali MJ; Tan D; Li W; Dhingra S; Brown RE
    Ann Clin Lab Sci; 2010; 40(2):126-34. PubMed ID: 20421623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell cycle biology of fibrolamellar hepatocellular carcinoma.
    Dhingra S; Li W; Tan D; Zenali M; Zhang H; Brown RE
    Int J Clin Exp Pathol; 2010 Nov; 3(8):792-7. PubMed ID: 21151393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.
    Ma S; Chan KW; Lee TK; Tang KH; Wo JY; Zheng BJ; Guan XY
    Mol Cancer Res; 2008 Jul; 6(7):1146-53. PubMed ID: 18644979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biology and clinical implications of CD133(+) liver cancer stem cells.
    Ma S
    Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Side population cell fractions from hepatocellular carcinoma cell lines increased with tumor dedifferentiation, but lack characteristic features of cancer stem cells.
    Nakayama M; Ogasawara S; Akiba J; Ueda K; Koura K; Todoroki K; Kinoshita H; Yano H
    J Gastroenterol Hepatol; 2014 May; 29(5):1092-101. PubMed ID: 24325739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma.
    Tomuleasa C; Soritau O; Rus-Ciuca D; Pop T; Todea D; Mosteanu O; Pintea B; Foris V; Susman S; Kacsó G; Irimie A
    J Gastrointestin Liver Dis; 2010 Mar; 19(1):61-7. PubMed ID: 20361077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
    Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
    Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of diagnostic utility and expression profiles of stem cell markers (CD133 and CD90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosis.
    Yilmaz G; Akyol G; Cakir A; Ilhan M
    Pathol Res Pract; 2014 Jul; 210(7):419-25. PubMed ID: 24702884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinomas expressing 'stemness'-related markers: clinicopathological characteristics.
    Kim H; Park YN
    Dig Dis; 2014; 32(6):778-85. PubMed ID: 25376296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
    Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
    Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD99 expression in hepatocellular carcinoma: an immunohistochemical study in the fibrolamellar and common variant of the tumour.
    Vasdev N; Nayak NC
    Indian J Pathol Microbiol; 2003 Oct; 46(4):625-9. PubMed ID: 15025359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active glycolytic metabolism in CD133(+) hepatocellular cancer stem cells: regulation by MIR-122.
    Song K; Kwon H; Han C; Zhang J; Dash S; Lim K; Wu T
    Oncotarget; 2015 Dec; 6(38):40822-35. PubMed ID: 26506419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of CD44, CD117 and CD133 in identification of cancer stem cells (CSC) in oral squamous cell carcinomas (OSCC).
    Mărgăritescu C; Pirici D; Simionescu C; Stepan A
    Rom J Morphol Embryol; 2011; 52(3 Suppl):985-93. PubMed ID: 22119814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring stemness gene expression and vasculogenic mimicry capacity in well- and poorly-differentiated hepatocellular carcinoma cell lines.
    Lirdprapamongkol K; Chiablaem K; Sila-Asna M; Surarit R; Bunyaratvej A; Svasti J
    Biochem Biophys Res Commun; 2012 Jun; 422(3):429-35. PubMed ID: 22580004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of tumorigenic liver cancer stem/progenitor cells.
    Ma S; Chan KW; Hu L; Lee TK; Wo JY; Ng IO; Zheng BJ; Guan XY
    Gastroenterology; 2007 Jun; 132(7):2542-56. PubMed ID: 17570225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma.
    Lingala S; Cui YY; Chen X; Ruebner BH; Qian XF; Zern MA; Wu J
    Exp Mol Pathol; 2010 Aug; 89(1):27-35. PubMed ID: 20511115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma.
    Zhu Z; Hao X; Yan M; Yao M; Ge C; Gu J; Li J
    Int J Cancer; 2010 May; 126(9):2067-78. PubMed ID: 19711346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Reversal of stemness in multidrug-resistant hepatocellular carcinoma cells by SIS3].
    Yan W; Wen T; Lin S; Liu Z; Yang W; Wu G
    Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):731-5. PubMed ID: 26813590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of CD133-positive stem cells in repeated recurrence of hepatocellular carcinoma after liver transplantation: a case report.
    Toshima T; Yoshizumi T; Uchiyama H; Ikegami T; Soejima Y; Ikeda T; Kawanaka H; Yamashita Y; Morita M; Oki E; Mimori K; Sugimachi K; Saeki H; Watanabe M; Shirabe K; Maehara Y
    Fukuoka Igaku Zasshi; 2013 Oct; 104(10):383-8. PubMed ID: 24511670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metastasis suppressor, NDRG1, inhibits "stemness" of colorectal cancer via down-regulation of nuclear β-catenin and CD44.
    Wangpu X; Yang X; Zhao J; Lu J; Guan S; Lu J; Kovacevic Z; Liu W; Mi L; Jin R; Sun J; Yue F; Ma J; Lu A; Richardson DR; Wang L; Zheng M
    Oncotarget; 2015 Oct; 6(32):33893-911. PubMed ID: 26418878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.